DK1830924T3 - Forebyggelse af thrombedannelse og/eller -stabilisering - Google Patents

Forebyggelse af thrombedannelse og/eller -stabilisering

Info

Publication number
DK1830924T3
DK1830924T3 DK05820601.2T DK05820601T DK1830924T3 DK 1830924 T3 DK1830924 T3 DK 1830924T3 DK 05820601 T DK05820601 T DK 05820601T DK 1830924 T3 DK1830924 T3 DK 1830924T3
Authority
DK
Denmark
Prior art keywords
stabilization
prevention
thrombus formation
thrombus
formation
Prior art date
Application number
DK05820601.2T
Other languages
English (en)
Inventor
Thomas Renne
Bernhard Nieswandt
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Application granted granted Critical
Publication of DK1830924T3 publication Critical patent/DK1830924T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05820601.2T 2004-12-23 2005-12-20 Forebyggelse af thrombedannelse og/eller -stabilisering DK1830924T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04030593 2004-12-23
PCT/EP2005/013714 WO2006066878A1 (en) 2004-12-23 2005-12-20 Prevention of thrombus formation and/or stabilization

Publications (1)

Publication Number Publication Date
DK1830924T3 true DK1830924T3 (da) 2013-05-21

Family

ID=34927953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05820601.2T DK1830924T3 (da) 2004-12-23 2005-12-20 Forebyggelse af thrombedannelse og/eller -stabilisering

Country Status (14)

Country Link
US (3) US8119137B2 (da)
EP (2) EP1830924B1 (da)
JP (1) JP5118492B2 (da)
KR (1) KR101277097B1 (da)
CN (1) CN101102819A (da)
AU (1) AU2005318464B2 (da)
BR (1) BRPI0519349A8 (da)
CA (1) CA2591786C (da)
DK (1) DK1830924T3 (da)
ES (1) ES2407965T3 (da)
MX (1) MX2007006997A (da)
PL (1) PL1830924T3 (da)
RU (1) RU2514878C2 (da)
WO (1) WO2006066878A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2709103T3 (es) 2002-08-28 2019-04-15 Dyax Corp Métodos para conservar órganos y tejidos
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2109457B1 (en) 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
US20090105142A1 (en) * 2007-08-23 2009-04-23 Genzyme Corporation Treatment with kallikrein inhibitors
US20110154517A1 (en) * 2007-10-22 2011-06-23 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
EP2145900A1 (en) 2008-07-15 2010-01-20 CSL Behring GmbH Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation
EP2103311A1 (en) 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EP2269597A1 (en) 2009-06-22 2011-01-05 CSL Behring GmbH CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis
EP2272874A1 (en) 2009-07-10 2011-01-12 CSL Behring GmbH Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
WO2012064758A2 (en) * 2010-11-08 2012-05-18 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
CA2829037C (en) 2011-03-09 2022-05-17 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
WO2013014092A1 (en) 2011-07-22 2013-01-31 Csl Behring Gmbh Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses
EP2548892A1 (en) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
BR112014003787A2 (pt) * 2011-08-23 2020-10-27 Synapse B.V. inibidores termoestáveis de ativação do sistema de coagulação sanguínea por contato com superfícies estranhas
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
US9574013B2 (en) * 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
JP2017501968A (ja) * 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
WO2015193457A1 (en) * 2014-06-18 2015-12-23 Csl Behring Gmbh Therapy using a factor xii inhibitor in a neurotraumatic disorder
CN107405399B (zh) 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
WO2016174103A1 (en) * 2015-04-28 2016-11-03 Ecole polytechnique fédérale de Lausanne (EPFL) Novel inhibitors of the enzyme activated factor xii (fxiia)
CA2993026A1 (en) 2015-07-21 2017-01-26 Dyax Corp. A monoclonal antibody inhibitor of factor xiia
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2017247004B2 (en) * 2016-04-06 2022-07-07 Csl Limited Method of treating atherosclerosis
CN111479587B (zh) 2017-12-15 2024-01-09 杰特有限公司 FXIIa抑制剂在治疗肾纤维化和/或慢性肾脏疾病中的应用
WO2019246176A1 (en) 2018-06-19 2019-12-26 Regeneron Pharmaceuticals, Inc. Anti-factor xii/xiia antibodies and uses thereof
EP3886982A1 (en) * 2018-11-28 2021-10-06 Oregon Health & Science University Therapeutic factor xii antibody
KR20220058530A (ko) 2019-07-08 2022-05-09 레졸루트 인크 혈장 칼리크레인 억제제의 제조 방법
JP7088892B2 (ja) 2019-10-11 2022-06-21 イビデン株式会社 組電池用断熱シート及び組電池
US20230295343A1 (en) * 2020-06-16 2023-09-21 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
AU2021401424A1 (en) 2020-12-18 2023-06-29 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating factor xii

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US4963657A (en) * 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
WO1994020535A1 (en) 1992-12-11 1994-09-15 Corvas International, Inc. ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
EP0719334A1 (en) 1993-09-14 1996-07-03 Genentech, Inc. Pharmaceutical compositions containing ecotin and homologs thereof
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
GB9800817D0 (en) 1998-01-16 1998-03-11 Bio Discovery Ltd Serine protease inhibitors
US6403381B1 (en) * 1998-06-08 2002-06-11 University Of Vermont And State Agriculture College Inhibition of coagulation in blood and blood products
AU760735B2 (en) * 1998-09-28 2003-05-22 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
ES2346189T3 (es) * 2001-01-11 2010-10-13 Life Sciences Research Partners Vzw Metodo y composicion farmaceutica para prevenir y/o tratar el sindrome de respuesta inflamatoria generalizada.
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2298278B1 (en) * 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
WO2004004640A2 (en) 2002-07-05 2004-01-15 Tetragrammaton Inc. Methods, compositions and kits for treating damage to excitable tissue
ES2709103T3 (es) * 2002-08-28 2019-04-15 Dyax Corp Métodos para conservar órganos y tejidos
US20040229778A1 (en) 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
US7544853B2 (en) 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
EP1673134A4 (en) 2003-09-12 2007-03-21 Marinepolymer Tech Inc RECEIVING VASCULAR ACCESS IN HEMODIALYSIS PATIENTS
GB0411145D0 (en) 2004-05-19 2004-06-23 Imp College Innovations Ltd Protease inhibitors and their therapeutic applications
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
GB0418877D0 (en) 2004-08-24 2004-09-29 Univ Edinburgh Heart
US20060104944A1 (en) 2004-11-18 2006-05-18 Mousa Shaker A Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use
ATE469650T1 (de) 2004-12-01 2010-06-15 Par Pharmaceuticals Inc Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz

Also Published As

Publication number Publication date
US8119137B2 (en) 2012-02-21
US8715672B2 (en) 2014-05-06
KR101277097B1 (ko) 2013-06-20
CN101102819A (zh) 2008-01-09
EP1830924A1 (en) 2007-09-12
US20130164301A1 (en) 2013-06-27
KR20070092303A (ko) 2007-09-12
US20080254039A1 (en) 2008-10-16
CA2591786A1 (en) 2006-06-29
US20120148688A1 (en) 2012-06-14
JP2008525342A (ja) 2008-07-17
RU2007123797A (ru) 2009-01-10
CA2591786C (en) 2013-07-16
AU2005318464A1 (en) 2006-06-29
EP2272565A3 (en) 2012-03-28
WO2006066878A1 (en) 2006-06-29
AU2005318464B2 (en) 2012-02-23
PL1830924T3 (pl) 2013-08-30
EP2272565A2 (en) 2011-01-12
JP5118492B2 (ja) 2013-01-16
BRPI0519349A2 (pt) 2009-01-20
MX2007006997A (es) 2007-10-10
BRPI0519349A8 (pt) 2017-09-12
RU2514878C2 (ru) 2014-05-10
EP1830924B1 (en) 2013-02-27
ES2407965T3 (es) 2013-06-17

Similar Documents

Publication Publication Date Title
DK1830924T3 (da) Forebyggelse af thrombedannelse og/eller -stabilisering
DK1891571T3 (da) Hæmning af spredning af uønskede koder og data
DK1628530T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK1793855T4 (da) Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK2072051T3 (da) Kombination af azelastin og mometason
DK1713503T3 (da) Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK3321359T3 (da) Variante former af uratoxidase og anvendelse deraf
DK3385267T3 (da) Syntese af boronestere og syreforbindelser
DK1771201T3 (da) Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom
DE602005027308D1 (de) Stabile salze von olanzapin
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DK1809622T3 (da) Inhibitorer af interaktionen mellem MDM2 og P53
DK1831154T3 (da) Fremstilling af pregabalin og relaterede forbindelser
DK1761222T3 (da) Indretninger og fremgangsmåder til magnetisk manipulering af intravaskulære indretninger
IS8305A (is) Bindandi smíðar og aðferðir við notkun þeirra
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK2308900T3 (da) Immunogene sammensætninger og fremgangsmåder til anvendelse
IS7344A (is) Stýrð efnasmíði síprasídóns og samsetninga af því
DK1440908T3 (da) Indsats og fremgangsmåde til fremstilling af drikkevarer
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK1831237T3 (da) Amidprolægemiddel af gemcitabin, sammensætninger og anvendelse deraf
DK2500325T3 (da) Forebyggelse og reducering af biofilmdannelse og planktonformering
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess